Last reviewed 2026-05-13 · How we verify

Sodium Polystyrene Sulfonate Oral Suspension [SPS]

University of California, Irvine · FDA-approved active Small molecule Quality 0/100

Sodium Polystyrene Sulfonate Oral Suspension [SPS] is a Small molecule drug developed by University of California, Irvine. It is currently FDA-approved. Also known as: Kayexalate.

Sodium Polystyrene Sulfonate Oral Suspension (SPS) is a marketed drug developed by the University of California, Irvine, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its patent until 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Sodium Polystyrene Sulfonate Oral Suspension [SPS]
Also known as	Kayexalate
Sponsor	University of California, Irvine
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sodium Polystyrene Sulfonate Oral Suspension [SPS] CI brief — competitive landscape report
Sodium Polystyrene Sulfonate Oral Suspension [SPS] updates RSS · CI watch RSS
University of California, Irvine portfolio CI

Frequently asked questions about Sodium Polystyrene Sulfonate Oral Suspension [SPS]

What is Sodium Polystyrene Sulfonate Oral Suspension [SPS]?

Sodium Polystyrene Sulfonate Oral Suspension [SPS] is a Small molecule drug developed by University of California, Irvine.

Who makes Sodium Polystyrene Sulfonate Oral Suspension [SPS]?

Sodium Polystyrene Sulfonate Oral Suspension [SPS] is developed and marketed by University of California, Irvine (see full University of California, Irvine pipeline at /company/university-of-california-irvine).

Is Sodium Polystyrene Sulfonate Oral Suspension [SPS] also known as anything else?

Sodium Polystyrene Sulfonate Oral Suspension [SPS] is also known as Kayexalate.

What development phase is Sodium Polystyrene Sulfonate Oral Suspension [SPS] in?

Sodium Polystyrene Sulfonate Oral Suspension [SPS] is FDA-approved (marketed).

Manufacturer: University of California, Irvine — full pipeline
Also known as: Kayexalate
Compare: Sodium Polystyrene Sulfonate Oral Suspension [SPS] vs similar drugs
Pricing: Sodium Polystyrene Sulfonate Oral Suspension [SPS] cost, discount & access